American Chronicle | Commentary: Upper Rhine Biovalley (Satis Shroff)
UPDATE: QUEBEC & ALSACE AXIS: French Connexion The main goal of the CQDM/Alsace BioValley joint program is to strengthen biomedical research in Quebec and Alsace by the alignment of international resources. This collaborative program also gives the opportunity for SME based in Quebec and Alsace to open up to new markets.
UPDATE: QUEBEC & ALSACE AXIS: French Connexion The main goal of the CQDM/Alsace BioValley joint program is to strengthen biomedical research in Quebec and Alsace by the alignment of international resources. This collaborative program also gives the opportunity for SME based in Quebec and Alsace to open up to new markets.
This program is not intended to fund research on new drugs for specific therapeutic segments. Rather, it is meant to finance the development of new technologies and processes that will have the power to facilitate the discovery or the development of new drugs.
This program promotes creativity, innovation, multidisciplinarity and collaborative efforts between academic institutions and private organizations [biotech/contract research organizations (CRO)]. Please note that multinational pharmaceutical companies are not eligible to this program.
No comments:
Post a Comment